Travera
Cambridge
About Travera
Travera commercializes a breakthrough measurement technology and biomarker developed in the Manalis Laboratory in the Koch Institute for Integrative Cancer Research at MIT. The core technology, a MEMS device called the Suspended Microchannel Resonator (SMR), is an exquisitely sensitive scale that can measure a small change in the weight of a single cancer cell. When cancer cells respond to cancer drugs, they start their process of dying by changing weight in just a few hours. The SMR can detect this tiny weight change. As most cancer cells die naturally within 1-2 days of being removed from the human body, speed is critical to distinguish between natural cell death and cell death induced by a cancer drug. It is this exquisite sensitivity that enables the SMR to detect a cancer cell’s response to a cancer drug while it is still a viable cell. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $13.6M
- Funding stage: Early Stage Venture
- Last round: Non-Equity Assistance (Jun 2023)
- Website: travera.com
- Phone: 650-576-7738
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/travera-92455 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.